New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma in early trial

NCT ID NCT07510100

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, modified to attack a protein called BCMA on myeloma cells. The study will enroll 17 participants to check for side effects and see how well the therapy works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institute of Science Tokyo Hospital

    Bunkyo-ku, Tokyo, 113-8519, Japan

    Contact

  • Japanese Red Cross Medical Center

    Shibuya-ku, Tokyo, 150-8935, Japan

    Contact

  • Nihon University Itabashi Hospital

    Itabashi-ku, Tokyo, 173-8610, Japan

    Contact